Medizone International Announces Agreement Retaining EMA Partners as Advisor and Investment Bank

KALAMAZOO, Mich., March 1, 2017 /PRNewswire/ -- Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure^®, the only EPA cleared hospital room disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens, announced today that the Company has entered into a definitive agreement with EMA Partners retaining them as the Company's advisor for financing and investment banking matters.

In late 2016, AsepticSure was cleared by the U.S. Environmental Protection Agency for entry into the United States market. The Company has been preparing for entry into a significant market that has a growing need for effective technologies that are capable of breaking the hospital acquired infection cycle. 

"We are very pleased to announce that Medizone International has reached an agreement to have EMA Partners serve as our advisor and investment bank. EMA Partners and its elite group of partners and life-science advisors have a remarkable track record of helping to create shareholder value in promising life-science companies," said David Esposito, Chairman and CEO of Medizone International. "As our team has completed several key milestones in the development of AsepticSure, we are preparing to scale our commercial operations in the United States and beyond.  We look forward to EMA Partners helping us realize the full potential of our business."

"EMA Partners looks forward to working with the seasoned management team and board at Medizone to explore strategic options to scale the business and to develop strategic partnerships with a broad range of industry players," said Andy Raeder, founding partner of EMA Partners. "We believe the AsepticSure technology has the potential to significantly impact the large unmet need of reducing hospital acquired infections. In addition, we see a large number of other compelling areas where this technology could be deployed to increase value creation for the Company."

Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial U.S. customers for AsepticSure. The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 in response to the increased prevalence and awareness of hospital acquired infections.  The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the Company released its AsepticSure system for use in Canada, and several other global markets. With EPA approval in late 2016, the Company is now prepared to expand into the U.S. market.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. 

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

About EMA Partners, LLC

EMA is focused on assisting its clients with mergers, acquisitions, divestitures, intellectual property licensing and sales, recapitalizations, transition planning and other transactional-based services.

We apply a process and perspective well suited to middle market clients across all geographies. With a professional staff of advisors from a variety of business disciplines, we are able to provide the strategy, analytics, marketing and transactional work to meet our clients' goals across industry verticals. This expertise is reflected in the wide range of transactions EMA has handled, ranging from outright sale of traditional industrial companies to licensing of sophisticated pre-revenue intellectual property.

Our focus has always been on the middle market, and on understanding client companies' objectives and strengths, communicating those strengths to prospective buyers or partners, and structuring transactions in a manner that maximizes value for our clients.

For more information, visit www.emapartners.com.  Securities -related services provided through Burch & Company, Inc., member FINRA/SIPC.

SOURCE Medizone International, Inc.